Accomplished

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Collaborative

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Enabling

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Innovative

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Focused

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.

Our products

Our product portfolio comprises marketed products, which provide an important source of revenue; branded investigational drugs, at different stages of development with partners or by Vectura alone; and generic investigational drugs.

Annual Report

Annual Report and Accounts for Year Ended 31 March 2014

 

In focus

Vectura Group plc – Preliminary Results for the year ended 31 March 2015

Chippenham, UK – 20 May 2015: Vectura Group plc (LSE: VEC) (“Vectura”), which specialises in the development of products for the treatment of airways-related diseases, announces today its preliminary results for the year ended 31 March 2015.

02 Jun 2015

Jefferies 2015 Healthcare Conference, New York – 2 June 2015

24 Sep 2015

Annual General Meeting